Document is current

Article History

Received: 24 February 2023

Accepted: 18 March 2024

First Online: 16 July 2024

Competing interests

: I.L.R.-C. reports personal honoraria from Agenus, Blueprint, BMS, PharmaMar, Genmab, Pfizer, AstraZeneca, Roche, GSK, MSD, Deciphera, Mersana, Merck Sereno, Novartis, Amgen, MacroGenics, Tesaro, and Clovis; honoraria to her institution from GSK, MSD, Roche, and BMS; consulting/advisory roles for AbbVie, Agenus, Advaxis, BMS, PharmaMar, Genmab, Pfizer, AstraZeneca, Roche/Genentech, GSK, MSD, Deciphera, Mersana, Merck Sereno, Novartis, Amgen, Tesaro and Clovis; research grant/funding from MSD, Roche and BMS (self) and MSD, Roche, BMS, Novartis, AstraZeneca and Merck Sereno (to institution); and travel support from Roche, AstraZeneca, and GSK. E.K. reports honoraria from AstraZeneca, Roche, Sanofi, Tesaro, and GSK; consulting/advisory roles for AstraZeneca, Roche, Sanofi, Tesaro and GSK; speakers’ bureau for AstraZeneca, Roche, Sanofi, Tesaro, and GSK; and research funding from AstraZeneca, Roche, Sanofi, Tesaro and GSK. M.L. reports consulting/advisory roles for Pierre Fabre, GSK, and Daiichi; research funding from Veracyte; and travel/accommodation/expenses from Mundi Pharma, Pfizer, GSK, and MSD. L.B.L. reports travel/accommodation/expenses from Servier. F.P. reports consulting/advisory role for AstraZeneca. F.S. reports honoraria from AstraZeneca, Clovis Oncology, MSD, GSK-Tesaro, and Sandoz (Novartis); consulting/advisory roles for AstraZeneca, GSK-Tesaro and MSD; speakers’ bureau for AstraZeneca, MSD, and GSK-Tesaro; and travel/accommodation/expenses from Roche, AstraZeneca, MSD, and GSK-Tesaro. E.C. reports the following, all for an immediate family member: employment with Sanofi; consulting/advisory role for MSD, BMS, Ipsen, and AstraZeneca; speakers’ bureau for BMS, Ipsen, AstraZeneca, and Janssen; research funding from Pfizer; and travel/accommodation/expenses from Janssen. O.L.S. reports honoraria from MSD and Clovis, and travel/accommodation/expenses from Eisai. A.A. reports honoraria from GlaxoSmithKline. F.J. reports honoraria from Clovis, Amgen, GSK, Ipsen, BMS, MSD, AstraZeneca, Astellas, Janssen and Bayer; consultancy from AstraZeneca, GSK, Janssen and Ipsen; travel/accommodation/expenses from Ipsen and GSK; participation on a data safety monitoring/advisory board for GSK; and participation on the GINECO guidelines committee. O.T. reports honoraria from Roche, MSD/Merck, Novartis/Sandoz, Pfizer, Lilly, AstraZeneca, Daiichi Sankyo, Eisai, Pierre Fabre, Seagen, and Gilead, and research funding from Roche, MSD/Merck and BMS. The remaining authors declare no competing interests.